PedAM
Pediatric Disease Annotations & Medicines
| Disease | hypercalcemia |
| Phenotype | C0687150|parathyroid carcinoma |
| Sentences | 4 |
| PubMedID- 22363762 | The average monthly increase in patients for the fda-approved orphan indication (hypercalcemia in patients with parathyroid carcinoma) was 0.03 (95% ci: 0.01–0.05). |
| PubMedID- 25667369 | Review of the literature revealed 4 case reports and a letter to the editor, all of which reported the successful treatment of resistant hypercalcemia associated with parathyroid carcinoma. |
| PubMedID- 25949409 | The drug was also approved for the treatment of hypercalcaemia in patients with a parathyroid carcinoma at the recommended oral starting dose of 30 mg once daily. |
| PubMedID- 20382129 | The second approved use of cinacalcet is for treating hypercalcemia in patients with inoperable parathyroid carcinoma. |
Page: 1